The Danish Royal Family has recently celebrated a significant milestone, as Princess Isabella, the second child of King Frederik and Queen Mary, turned 18. To mark this occasion, the royal family released a series of official portraits showcasing the young princess in her first tiara, a turquoise daisy bandeau gifted by her grandmother, the former Queen Margrethe II. The images, taken in the grandeur of Frederik VIII's Palace at Amalienborg, highlight a moment of tradition and transition for the princess, who is now second in line to the throne.

In a delightful twist, a behind-the-scenes photo captured by Queen Mary reveals a more personal side of Princess Isabella. The candid snapshot shows the princess, dressed in full royal regalia, clutching her cell phone with a surprised smile. This moment, shared on the royal family's social media, underscores the blend of royal tradition and the relatable aspects of modern youth, resonating with fans worldwide.

The official portraits not only celebrate Princess Isabella's coming of age but also her entry into the Order of the Elephant, Denmark's oldest and most prestigious order of chivalry. The honor, which includes wearing a sash and a miniature portrait of her father, King Frederik X, is a testament to her growing role within the royal family and the nation.

The release of these images has sparked admiration and warmth from the public, with many praising the balance between the solemnity of royal duties and the genuine joy of a young woman celebrating her birthday. Princess Isabella's 18th birthday marks a new chapter in her life, one that bridges the rich heritage of the Danish monarchy with the dynamic spirit of a new generation.

Inozyme Pharma, Inc. has reported encouraging interim data from its ENERGY 3 trial, showcasing INZ-701's potential to alter the disease trajectory in patients with ENPP1 Deficiency. The clinical-stage biopharmaceutical company highlighted sustained increases in phosphate levels alongside a favorable safety and immunogenicity profile, marking a significant step forward in addressing this rare disease.

The ENERGY 3 trial, which completed enrollment in January 2025, is on schedule to deliver topline data in the first quarter of 2026. Douglas A. Treco, Ph.D., CEO and Chairman of Inozyme Pharma, expressed optimism about the trial's progress, noting the absence of patient dropouts, dose adjustments, or discontinuations. This consistency across key metrics underscores the potential of INZ-701 to become the first approved therapy for ENPP1 Deficiency, a condition with significant unmet medical needs.

Adding to the company's momentum, Petra Duda, M.D., Ph.D., has been appointed as Chief Medical Officer. Her expertise is expected to bolster Inozyme Pharma's clinical development efforts as it advances INZ-701 through pivotal trials. The appointment comes at a critical juncture, with the company poised to make significant strides in rare disease therapeutics.

As Inozyme Pharma continues to navigate the clinical development landscape, the progress of the ENERGY 3 trial and the strategic addition to its leadership team underscore its commitment to innovation in rare disease treatment. With the anticipation of topline data in early 2026, the medical and investment communities are closely watching INZ-701's journey toward potential approval and its impact on patients with ENPP1 Deficiency.